Efficacy and safety of mirikizumab in the treatment of inflammatory bowel disease: A meta-analysis

Abstract

Background: This meta-analysis explores the efficacy and safety of mirikizumab in treating IBD. Methods: A comprehensive search was conducted encompassing randomized controlled trials examining the efficacy of mirikizumab in treating IBD across PubMed, Embase, Cochrane Library, and Web of Science, with a search deadline of November 1, 2023. Quality assessment leaned on the Cochrane manual risk-of-bias evaluation, while Stata 15 undertook the data analysis. Results: Three randomized controlled studies involving 1602 individuals were finally included. Our meta-analysis suggested that mirikizumab can improve clinical remission (RR = 2.11, 95% CI [1.74, 2.55]), clinical response (RR = 1.68, 95% CI [1.50, 1.89]), endoscopic remission (RR = 1.95, 95% CI [1.65, 2.31]), histologic-endoscopic mucosal improvement (RR = 1.92, 95% CI [1.60, 2.32]) in inflammatory bowel disease (IBD). Conclusion: According to our meta-analysis, mirikizumab is a promising drug in the treatment of IBD.